NCT01826474 - Phase IIb Study of PRO045 in Subjects With Duchenne Muscular Dystrophy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

August 31, 2016

Study Completion Date

August 31, 2016

Conditions

Duchenne Muscular Dystrophy

Interventions

DRUG

PRO045, 0.15 mg/kg/week

Subcutaneous injection

DRUG

PRO045, 1.0 mg/kg/week

Subcutaneous injection

DRUG

PRO045, 3.0 mg/kg/week

Subcutaneous injection

DRUG

PRO045, 6.0 mg/kg/week

Subcutaneous injection

DRUG

PRO045, 9.0 mg/kg/week

Subcutaneous injection

DRUG

PRO045, selected dose

Subcutaneous injection

Trial Locations (6)

UZ Leuven, Leuven

Institut de Myologie, Paris

Policlinico Universitario Agostino Gemelli, Roma

Leids Universitair Medisch Centrum, Leiden

Great Ormond Street Hospital for Children, London

Institute of Genetic Medicine International Centre for Life, Newcastle